

Unmet need in oncology

- › Current cancer therapies insufficiently address metastasis, particularly in colorectal cancer
- › Key metastatic drivers (S100A4, MACC1) are associated with poor survival when highly expressed, yet remain untargeted by existing therapies

Metastrict is developing a novel metastasis inhibitor **MSt-001 (E12)** which:

- › Strongly reduces expression of the key metastatic drivers MACC1 and S100A4
- › Decreases metastasis formation as well as their proliferation
- › Can potentially overcome chemo-resistance

TECHNOLOGY

MSt-001 (E12)

- › Novel small-molecule inhibitor to block metastasis at its source by preventing the expression of key drivers MACC1 & S100A4
- › Addresses migration and chemotherapy resistance at the transcriptional level in metastatic colorectal cancer
- › More fundamental and durable approach than downstream, post-translational interventions
- › Biomarker-driven, targets resistance and metastasis formation at its core

Figure 1: Effect of the compound MSt-001 inhibitor (E12) on HCT116 cell wound healing capacity

Wound confluence in % monitored over 72 h using the IncuCyte Live cell imaging system. All compounds were tested from 0.1 - 15 μ M

Figure 2: In vivo imaging of the mice after 21 days of treatment

CDX metastasis mouse model for evaluation of the capability of MSt-001 (E12) to reduce the metastatic phenotype of HCT116/CMVp-Luc colorectal cancer cells

E12, Wound Confluence, HCT116




Figure 1




Figure 2

INTELLECTUAL PROPERTY

MSt-001 (E12) Inhibitors of S100A4 transcription
EP priority application (05/2025)

2 more patents in the patent portfolio focusing on inhibition of S100A4 and MACC1 through niclosamide and statins repurposing approaches (WO2012143377A1; WO2020169812A1)

RESEARCH EXPERTISE

- › The therapy was developed by the group of Prof. Dr. Ulrike Stein, a key opinion leader in metastatic cancer, discoverer of metastatic drivers
- › Her lab specializes in Translational Oncology of Solid Tumors

PARTNER WITH US

We are seeking

- › Co-development opportunities



PROF. ULRIKE STEIN



PAUL CURTIS SCHÖPE